To determine if X4 - ZFNs
impacted cell growth or viability in the absence of HIV, we first compared CD4 counts over time between the uninfected X4 - ZFN and R5 - ZFN control mice.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain
growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize
cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange
impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
In fact, associations of cancer
cells with the normal peritumoral microenvironment can profoundly
impact tumor
growth and development.
It is the first time that evidence has been found to suggest that local anaesthetic could affect tooth
cell growth and potentially
impact upon tooth development.
Together the stable disruption of CXCR4 as determined by both the surveyor nuclease assay and flow cytometry suggests that CXCR4 disruption did not negatively
impact cell viability or
growth in humanized NSG mice over a two - month period.
For subsequent experiments we used an MOI of 600 as this provided near - maximal disruption efficiency with limited
impact on
cell growth.
These secretions, in combination with
growth, death, and steric interactions between
cells, strongly
impact biofilm spatial organization [16, 27 — 30].
Dr. Kulkarni's research focuses on investigating signaling pathways
impacting growth and function of pancreatic islet
cells with the long - term goal of improving therapeutic approaches for the treatment of type 1 and type 2 diabetes and obesity - associated conditions.
Furthermore, since malignant
cells exploit early developmental programmes for their survival and
growth, a deeper understanding of human development will have
impact in cancer research.
Other factors will also
impact the evolution of adhesion phenotypes, including the relative advantage of highly - adhesive
cells against less - adhesive
cells in direct competition [54], and the trade - off between competitive surface adhesion and the ability to disperse to new habitats for later
growth [38, 40, 83].
Arabinosylation of a Yariv - Precipitable
Cell Wall Polymer
Impacts Plant
Growth as Exemplified by the Arabidopsis Glycosyltransferase Mutant ray 1, Dwiyanti, Gille, S, Sharma V, Baidoo EE, Keasling JD, Scheller HV, Pauly M, Molecular Plant, 6 (4): 1369 - 72.
These processes included dust deposition, and ocean acidification and warming, which were shown to have a significant
impact on oceanic phytoplankton
growth,
cell size and primary productivity, biological N2 fixation, phytoplankton distribution and community composition.
However, elevated atmospheric CO2 concentrations and ocean acidification may also have an adverse
impact on diatom
growth, causing a decrease in
cell size and possible further changes in phytoplankton composition.
The Zika virus is known to negatively
impact the
growth of fetal brains and a group of researchers publishing in the journal
Cell Stem Cell have investigated the effect of Zika on the adult brain reporting that infection can lead to cell death and reduced proliferat
Cell Stem
Cell have investigated the effect of Zika on the adult brain reporting that infection can lead to cell death and reduced proliferat
Cell have investigated the effect of Zika on the adult brain reporting that infection can lead to
cell death and reduced proliferat
cell death and reduced proliferation.
Her goal is to define the molecular architecture and functional significance of a niche, determine how tumor
growth impacts the niche, learn how benign and malignant
cells compete within a niche, and use this knowledge to design precisely targeted anti-cancer treatments that spare normal bone marrow and improve the efficacy of stem
cell - based therapies.
HIV - 1 neutralization is
impacted by the PBMC donor used for both virus
growth and target
cells, and the effects are neutralization reagent - specific
Sclerostin is a protein produced by bone
cells which has a negative
impact on the formation of bone when expressed at high levels by decreasing bone formation, and IGF - 1 is a hormone associated with the
growth of bone.
Curcumin inhibits interleukin 8 production and enhances interleukin 8 receptor expression on the
cell surface:
impact on human pancreatic carcinoma
cell growth by autocrine regulation.
Vitamin D is more than a benefit for bone health, it
impacts heart health, hormone regulation, immune system responses, and even brain
cell growth.
They looked for indicators that the pomegranate juice was
impacting the
growth and the spread of the cancer
cells within the mice.
Building off of the data in hOSA, Dr. Baldanza's study will address the hypothesis that HH signaling is also active in cOSA, and targeted inhibition of the pathway will negatively
impact and slow OSA
cell growth and survival.